Randomized Study with Combined Therapy
A prospective, randomized, multicenter, study to evaluate the benefit of IVL combined with drug-coated balloons vs standalone DCB in heavily calcified fem-pop lesions followed out to 24 months. It also includes an all-comers registry arm to assess the real-world acute performance of IVL in lower extremities, including iliac, femoral, fem-pop, popliteal and infrapopliteal lesions.
DISRUPT PAD III
By The Numbers
DISRUPT PAD III
By The Numbers
Countries Included in DISRUPT PAD III
Ready to Make Waves with Shockwave IVL?
We're excited about IVL's potential in aortic stenosis, too!
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Get Crackin with Shockwave IVL Today
Wow - you're ready to start cracking, aren't you?
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.